These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 9086571)
1. False-positive results of basal and pentagastrin-stimulated calcitonin in non-gene carriers of multiple endocrine neoplasia type 2A. Hernández G; Simó R; Oriola J; Mesa J Thyroid; 1997 Feb; 7(1):51-4. PubMed ID: 9086571 [TBL] [Abstract][Full Text] [Related]
2. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Marsh DJ; McDowall D; Hyland VJ; Andrew SD; Schnitzler M; Gaskin EL; Nevell DF; Diamond T; Delbridge L; Clifton-Bligh P; Robinson BG Clin Endocrinol (Oxf); 1996 Feb; 44(2):213-20. PubMed ID: 8849577 [TBL] [Abstract][Full Text] [Related]
3. [Mutation of the RET proto-oncogene in type 2A multiple endocrine neoplasia Chinese families and the application of pentagastrin stimulation test in diagnosis and follow-up]. Yao B; Liu X; Chen X; Dong TT; Liang H; Weng JP Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):914-8. PubMed ID: 18261274 [TBL] [Abstract][Full Text] [Related]
4. Germline mutations of the RET proto-oncogene in pedigree with MEN type 2A: DNA analysis and its implications for pediatric surgery. Shimotake T; Iwai N; Inoue K; Inazawa J; Nishisho I J Pediatr Surg; 1996 Jun; 31(6):779-81. PubMed ID: 8783101 [TBL] [Abstract][Full Text] [Related]
5. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218 [TBL] [Abstract][Full Text] [Related]
6. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030 [TBL] [Abstract][Full Text] [Related]
7. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103 [TBL] [Abstract][Full Text] [Related]
8. Multiple endocrine neoplasia type 2A. Study of a family. Correia MJ; Lopes LO; Bugalho MJ; Cristina L; Santos AI; Bordalo AD; Pinho B; da Silva HL; Gonçalves MD; Ribeiro C; Tuna JL Rev Port Cardiol; 2000 Jan; 19(1):11-31. PubMed ID: 10731788 [TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of seven Mediterranean families with multiple endocrine neoplasia type 2A. Oriola J; Hernandez C; Simo R; Barcelo A; Casamitjana R; Vilardell E; Rivera-Fillat F Clin Endocrinol (Oxf); 1996 Feb; 44(2):207-12. PubMed ID: 8849576 [TBL] [Abstract][Full Text] [Related]
10. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Caron P; Attié T; David D; Amiel J; Brousset F; Roger P; Munnich A; Lyonnet S J Clin Endocrinol Metab; 1996 Jul; 81(7):2731-3. PubMed ID: 8675603 [TBL] [Abstract][Full Text] [Related]
11. RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Pasini B; Rossi R; Ambrosio MR; Zatelli MC; Gullo M; Gobbo M; Collini P; Aiello A; Pansini G; Trasforini G; degli Uberti EC Surgery; 2002 Apr; 131(4):373-81. PubMed ID: 11935126 [TBL] [Abstract][Full Text] [Related]
12. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060 [TBL] [Abstract][Full Text] [Related]
13. Failure of pentagastrin-stimulated calcitonin testing in early manifestation of familial medullary thyroid cancer. Pirich C; Rendl G; Hauser-Kronberger C; Häusler I Wien Klin Wochenschr; 2012 Oct; 124(19-20):723-4. PubMed ID: 22965292 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Kambouris M; Jackson CE; Feldman GL Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338 [TBL] [Abstract][Full Text] [Related]
15. A family of multiple endocrine neoplasia type 2A: genetic analysis and clinical features. Morita H; Daidoh H; Nagata K; Okano Y; Sudoh Y; Maruyama T; Sarui H; Ishizuka T; Akagi K; Nishisho I; Yasuda K Endocr J; 1996 Feb; 43(1):25-30. PubMed ID: 8732448 [TBL] [Abstract][Full Text] [Related]
16. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Pina G; Dubois S; Murat A; Berger N; Niccoli P; Peix JL; Cohen R; Guillausseau C; Charrie A; Chabre O; Cornu C; Borson-Chazot F; Rohmer V; Clin Endocrinol (Oxf); 2013 Mar; 78(3):358-64. PubMed ID: 22913268 [TBL] [Abstract][Full Text] [Related]
17. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. Skinner MA; Moley JA; Dilley WG; Owzar K; Debenedetti MK; Wells SA N Engl J Med; 2005 Sep; 353(11):1105-13. PubMed ID: 16162881 [TBL] [Abstract][Full Text] [Related]
18. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. Lips CJ; Landsvater RM; Höppener JW; Geerdink RA; Blijham G; van Veen JM; van Gils AP; de Wit MJ; Zewald RA; Berends MJ N Engl J Med; 1994 Sep; 331(13):828-35. PubMed ID: 7915822 [TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis of multiple endocrine neoplasia type 2A. Pegoraro RJ; Hacking DJ; Buck RH; Rom L; Lanning PA; Berger GM S Afr Med J; 1998 Jan; 88(1):39-42. PubMed ID: 9539934 [TBL] [Abstract][Full Text] [Related]
20. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Wells SA; Chi DD; Toshima K; Dehner LP; Coffin CM; Dowton SB; Ivanovich JL; DeBenedetti MK; Dilley WG; Moley JF Ann Surg; 1994 Sep; 220(3):237-47; discussion 247-50. PubMed ID: 7916559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]